{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-25-000052","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.941130+00:00","generated_at":"2026-05-22T07:18:09.977582+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xencor Q1 net loss narrows to $48.4M; CDO Valente resigns, Phase 2b UC study on track","bullets":["Q1 revenue $32.7M (up from $16.0M YoY); net loss $48.4M (-$0.66 EPS) versus $73.4M (-$1.20 EPS) prior year.","Cash $693.5M at March 31; expects year-end 2025 cash $535-585M, funding operations into 2028.","Nancy Valente, EVP & CDO, to resign June 6, 2025, remain as senior advisor; clinical leaders report to CEO.","XmAb942 interim Phase 1 shows half-life >71 days, supports Q12W maintenance dosing; Phase 2b XENITH-UC starts H2 2025.","Earned $12.5M milestone from Incyte for tafasitamab sBLA acceptance, $2.0M from Vir for tobevibart Phase 3 start."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-25-000052","json":"https://secwatch.observer/filing/0001326732-25-000052.json","markdown":"https://secwatch.observer/filing/0001326732-25-000052.md","text":"https://secwatch.observer/filing/0001326732-25-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/0001326732-25-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/xncr-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:18:09.977582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"add70724c8","claim":"Nancy Valente resigned as Executive Vice President and Chief Development Officer at Xencor Inc.","evidence_excerpt":"On May 5, 2025, Nancy Valente, Executive Vice President and Chief Development Officer, notified the Company of her intention to resign from the Company effective June 6, 2025, and remain as a senior advisor.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/0001326732-25-000052-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President and Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}